Peptide Drug Discovery through Secondary Structure Control.
Peptide research just got a serious upgrade. The latest work from Demizu and colleagues shows that controlling secondary structure—basically, shaping how a peptide folds—can push peptide discovery far beyond old limitations. Forget the idea that peptides are just floppy intermediates between small molecules and big biologics. With smart design, secondary structure becomes the key to creating high-performance research compounds.
Chem Pharm Bull (Tokyo)
by Demizu Y
“Peptide Drug Discovery through Secondary Structure Control. Demizu Y(1)(2)(3). Author information: (1)Division of Organic Chemistry, National Institute of Health Sciences. (2)Graduate School of Medical Life Science, Yokohama City University. (3)Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University. Peptides have long occupied an intermediate position between small molecules and macromolecular therapeutics in drug discovery, yet their practical application has been limited by intrinsic conformational flexibility and insufficient drug-like properties. Recent advances in the deliberate control of peptide secondary structure have fundamentally altered this perception, enabling peptides to function as designable molecular platforms. In particular, rational modulation of α-helical conformations has expanded the functional scope of peptides to include protein-protein interaction (PPI) inhibition, membrane-active antimicrobial functions, and intracellular drug delivery. This review summarizes our research on peptide drug discovery guided by secondary structure control as a unifying design principle. By emphasizing spatial organization within α-helical frameworks rather than primary sequence alone, we demonstrate how molecular recognition, membrane interaction, and cellular uptake can be systematically regulated. These concepts are demonstrated through the development of α-helix-based protein-protein interaction inhibitory peptides, amphipathic antimicrobial peptides with reduced cytotoxicity, and cell-penetrating peptides optimized for nucleic acid delivery. Furthermore, the extension of stabilized helical peptides to targeted protein degradation highlights their potential beyond conventional inhibition. In addition, we have worked to translate these research outcomes into societal implementation, with particular emphasis on regulatory development for peptide therapeutics. As part of these efforts, we contributed to the establishment and finalization of guidelines for the quality assessment and nonclinical safety evaluation of mid-sized peptide drugs. Collectively, these studies establish secondary structure control as a foundational concept for next-generation peptide therapeutics and their translation into clinically and socially viable modalities.”
Here’s the shift: Focus on α-helical frameworks, not just the sequence of amino acids. By locking peptides into defined shapes, researchers can dial in properties like protein-protein interaction (PPI) blockage, membrane disruption for antimicrobial effects, and even intracellular delivery. That means more potent PPI inhibitors, less toxic antimicrobial peptides, and cell-penetrating peptides optimized for delivering nucleic acids.
Key advances from the Demizu group:
Helical peptides that inhibit tough PPIs—targets once considered "undruggable"
Amphipathic antimicrobial peptides with lower cytotoxicity, hitting bugs not human cells
Cell-penetrating peptides fine-tuned for nucleic acid transport
Stabilized helix designs extended to targeted protein degradation—think beyond just blocking, to actively removing unwanted proteins
The research doesn’t stop in the lab. Demizu’s team helped set new guidelines for mid-sized peptide quality and safety evaluation, moving the field closer to real-world application.
If you’re diving into peptide discovery or looking to innovate on delivery and targeting, secondary structure control is now a core principle. The field is shifting from sequence-first to structure-first thinking, opening up new targets and applications.
Check out the peptide research index to see where these strategies are showing up in current projects. There’s never been a better time to experiment with peptide design.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.